Medicare coverage process
This article was originally published in The Gray Sheet
Executive Summary
Recently released Health Care Financing Administration notice describing procedures and timeframes for obtaining coverage decisions ("The Gray Sheet" April 26, p. 3) fails to provide an "opportunity for stakeholders to have an early, collaborative meeting with" HCFA staff "so that a written, mutual agreement may be reached on what specific information" is needed to make a coverage determination, Medical Alley says in an April 28 letter to Jeffrey Kang, director of HCFA's Office of Clinical Standards and Quality. The lack of such an agreement "creates a tenuous foundation for the entire coverage decision-making process," according to the group, which plans to discuss the matter further with Kang during a May 12 conference call
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.